Precision Medicine in Pediatric Oncology- Is it the Way Forward?

Article Sidebar

PDF
Published: Oct 15, 2021
DOI: https://doi.org/10.47191/ijpbms/v1-i7-05
Keywords:
Precision Medicine, Targeted Therapy, Individualized Medicine, Pediatric Cancer

Main Article Content

Himani Dhingra
Assistant Professor, Department of Pediatrics, Pt. BDS University of Health Sciences, Rohtak, Haryana
Pankaj Abrol
Professor and Head, Department of Pediatrics, SGT Medical College and research institute, Budhera, Gurugram

Abstract

Precision medicine is currently an emerging approach for the treatment of childhood cancer. The use of improved molecular diagnostic techniques has facilitated the identification of actionable molecular targets and hence additional therapeutic opportunities. Next generation sequencing (NGS) has revolutionized our understanding of pediatric cancer and fueled the personalized approach to cancer treatment. Treatment of patients with pediatric cancer is not synonymous with treatment in a mini adult. Pediatric cancers have different genetic constitution and fewer molecular targets as compared to adult tumors. This overview discusses the diagnostic and therapeutic advancements along with some of the important clinical implications and the future prospects of precision medicine in pediatric oncology.

Article Details

How to Cite
Himani Dhingra, & Pankaj Abrol. (2021). Precision Medicine in Pediatric Oncology- Is it the Way Forward?. International Journal of Pharmaceutical and Bio Medical Science, 1(7), 107–111. https://doi.org/10.47191/ijpbms/v1-i7-05
Issue
Vol. 1 No. 7 (2021): Volume 01 Issue 07 October 2021
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Kalia M. Personalized oncology: Recent advances and future challenges. Metabolism. 2013;62(Suppl. 1):S11–S14. doi: 10.1016/j.metabol.2012.08.016.

II. Garraway L.A, Verweij J, Ballman K.V. Precision oncology: An overview. J Clin Oncol. 2013; 31:1803–1805.

doi: 10.1200/JCO.2013.49.4799.

III. Mendelsohn J. Personalizing oncology: Perspectives and prospects. J Clin Oncol. 2013; 31:1904– 1911.

doi: 10.1200/JCO.2012.45.3605.

IV. Blumenthal G.M., Mansfield E , Pazdur R. Next-generation sequencing in oncology in the era of precision medicine. JAMA Oncol. 2016;2:13–14. doi: 10.1001/jamaoncol.2015.4503.

V. Joseph L, Cankovic M, Caughron S et al. The spectrum of clinical utilities in molecular pathology testing procedures for inherited conditions and cancer: a report of the Association for Molecular Pathology. J Mol Diagn. 2016;18:605–619.

VI. Ahmed A.A, Vundamati S.D, Farooqi S.M et al. Precision Medicine in Pediatric Cancer: Current Applications and Future Prospects. High Throughput. 2018 Dec; 7(4): 39.

VII. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803-820.

VIII. Lodrini M, Sprussel A, Astrahantseff K, et al. Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma. Oncotarget. 2017;8:85234–85251

IX. Krumbholz M, Hellberg J, Steif B, et al. Genomic EWSR1 fusion sequence as highly sensitive and dynamic plasma tumor marker in Ewing sarcoma. Clin Cancer Res. 2016; 22:4356–4365

X. FDA Approval for Gleevec for Children with Ph+ ALL, Oncology Times: February 25th, 2013 - Volume 35 - Issue 4 - p 12. doi: 10.1097/01.COT.0000427834.60711.5c

XI. Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia [news release]. Basel, Switzerland: Novartis; March 22, 2018. https://www.novartis.com/news/media-releases/novartis-drug-tasignar-approved-fda-treat-children-rare-form-leukemia

XII. Jarnicki A, Putoczki T, Ernst M. Stat3: linking inflammation to epithelial cancer – more than a “gut” feeling? Cell Div. 2010;5:14.

doi: 10.1186/1747-1028-5-14. 1747-1028-5-14

XIII. Groner B, Von Manstein V. Jak Stat signaling and cancer: opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol. (2017) 451:1–14. doi:10.1016/j.mce.2017.05.033

XIV. Kiladjian JJ. The spectrum of JAK2-positive myeloproliferative neoplasms. Hematol Am Soc Hematol Educ Program. 2012:561–566. doi: 10.1182/asheducation-2012.1.561

XV. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371:1005–15. doi: 10.1056/NEJMoa1403088

XVI. Tasian K.S, Assad A, Hunter S.D, et al. A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase. Blood. 2018; 132 (Supplement 1): 555

XVII. Pemmaraju N, Kantarjian H, Kadia T, et al. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15:171–176.

doi: 10.1016/j.clml.2014.08.003

XVIII. Drenberg CD, Shelat A, Dang J, et al. A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nat Commun.2019;10:2189.

doi: 10.1038/s41467-019-09917-0

XIX. Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006 Dec 1;108(12):3654-3661. doi: 10.1182/blood-2006-03-009233.

XX. Morris SW, Kirstein MN, Valentine MB et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non‐Hodgkin's lymphoma. Science. 1994; 263: 1281–1284.

XXI. Mossé YP, Laudenslager M, Longo L et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455: 930–935.

XXII. Mossé YP, Lim MS, Voss SD et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large‐cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013; 14: 472–480.